SCHEMBL4408645

SCHEMBL4408645

COc1cccc(-c2ccc3c(c2)NC(=O)C3=Cc2[nH]c(C)c(CCC(=O)O)c2C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 16/20 1.00
▸ FGFR1 P11362 15/20 1.00
▸ PDGFRB P09619 14/20 1.00
▸ EGFR P00533 7/20 1.00
▸ SRC P12931 1/20 0.70
▸ FLT3 P36888 5/20 0.69
▸ FLT4 P35916 2/20 0.69
▸ KIT P10721 1/20 0.69
▸ AURKB Q96GD4 4/20 0.66
▸ CHEK1 O14757 3/20 0.66
▸ AURKA O14965 2/20 0.66
▸ RET P07949 2/20 0.66
▸ FLT1 P17948 2/20 0.66
▸ MAP4K2 Q12851 2/20 0.66
▸ STK3 Q13188 2/20 0.66
▸ GAK O14976 1/20 0.66
▸ RPS6KA5 O75582 1/20 0.66
▸ RPS6KA4 O75676 1/20 0.66
▸ LATS1 O95835 1/20 0.66
▸ CSNK2A2 P19784 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4408641 1.00 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL29435065 0.93 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4408521 0.92 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4408517 0.92 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4414238 0.92 KDR (0.84) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4414235 0.92 KDR (0.84) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4408686 0.90 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4411069 0.90 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL4411073 0.90 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC
SCHEMBL29678231 0.90 KDR (1.00) KDRFGFR1PDGFRBEGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105151-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-05 — — US claimed
US-6395734-B1 ANTICANCER AGENTS SUGEN, INC. 2002-05-28 — — US claimed
EP-2020408-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors Sugen, Inc. (US) 2009-02-04 — — EP disclosed
US-7119090-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2006-10-10 — — US disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 — — US disclosed
US-20030105151-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-05 — — US disclosed
US-6395734-B1 ANTICANCER AGENTS SUGEN, INC. 2002-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105151-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors DMPK, PDPK1, PLK2 KDR 1066/4885FGFR1 930/4885PDGFRB 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback